[A18-36] Olaparib (ovarian, fallopian tube, peritoneal cancer) - Benefit assessment according to §35a Social Code Book V

Last updated 17.09.2018

Project no.:
A18-36

Commission:
Commission awarded on 05.06.2018 by the Federal Joint Committee (G-BA).

Report type:
Dossier assessment

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Patients with platinum-sensitive relapsed high-grade ovarian cancer

Result of dossier assessment:

Serous epithelial ovarian cancer: hint of minor added benefit. Non-serous epithelial ovarian cancer: added benefit not proven

Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant pages of the G-BA website: Nutzenbewertungsverfahren zum Wirkstoff Olaparib (neues Anwendungsgebiet: high-grade epitheliales Ovarialkarzinom, Eileiterkarzinom oder primäres Peritonealkarzinom) and Nutzenbewertungsverfahren zum Wirkstoff Olaparib (Aufhebung des Orphan-Drug-Status).

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

2018-12-06 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.